Premium
Emerging Biological Therapies in Systemic Lupus Erythematosus
Author(s) -
Mount G R,
Gilliland W R
Publication year - 2008
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100436
Subject(s) - medicine , organ system , disease , systemic disease , systemic inflammation , rash , arthritis , immunology , systemic lupus erythematosus , inflammation , dermatology , autoimmune disease , lupus erythematosus , thrombosis , malar rash , intensive care medicine , autoantibody , pathology , antibody , anti nuclear antibody
Systemic lupus erythematosus (SLE) is a prototypic inflammatory autoimmune disorder characterized by multisystem involvement and fluctuating disease activity. Symptoms range from rather mild manifestations such as rash or arthritis to life‐threatening end‐organ manifestations such as glomerulonephritis or thrombosis. Virtually every organ system is subject to potential damage. Symptoms typically wax and wane over the course of the disease; yet unfortunately, many patients will experience a slow decline in their health because of the ongoing systemic inflammation. Effective treatment must be individualized and is often based on the specific manifestations that are seen in each patient. In a similar manner, prognosis is also dependent on the severity and the specific organ systems involved.